HealthPartners Institute: Diabetes Mellitus, Type 2 trials
The registry lists 14 Diabetes Mellitus, Type 2 studies with HealthPartners Institute as lead sponsor. 1 are open to participants now and 4 have results posted.
Phase 2 1Phase 3 1Phase 4 1No phase 12(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Clinical Decision Support With Continuous Glucose Monitoring Data for Managing Type 2 DiabetesEnrolling by invitationNCT07394075
- Nutrition-Focused Approach During CGM Initiation: A Qualitative StudyCompletedNCT05988957Results posted
- IGNITE (Impact of Glucose moNitoring and nutrItion on Time in rangE)CompletedNCT05516797Not applicableResults posted
- Comparing Self Monitored Blood Glucose (SMBG) to Continuous Glucose Monitoring (CGM) in Type 2 DiabetesCompletedNCT01237301Not applicableResults posted
- Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 DiabetesCompletedNCT00993824Phase 2/3Results posted
- Glucose Monitoring Comparison in Primary CareCompletedNCT05222815Not applicable
- Weight Loss Clinical Decision SupportActive, not recruitingNCT05198765Not applicable
- Continuous Glucose Monitoring Self-Monitored Blood Glucose Type 2 Therapy Matrix DefinitionCompletedNCT01390610
- The Impact of Food on Blood Sugar in People With Type 2 DiabetesCompletedNCT01237314
- Modal Day Analysis of Self Monitoring Blood Glucose Versus Continuous Glucose MonitoringCompletedNCT01072565Not applicable
- Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic ControlCompletedNCT00806520
- Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide or Once-Weekly ExenatideCompletedNCT00803920
- Observational Study of Interstitial Glucose Monitoring With Continuous Glucose Monitoring to Track Patients Treated With ExenatideCompletedNCT00569907
- Impact of Self-Monitoring Blood Glucose Frequency on Glycemic Control in Patients With Type 2 DiabetesCompletedNCT00202033Phase 4